CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE

Year 2020, Volume: 7 Issue: 1, 1 - 4, 29.02.2020

Beiza Chatzisali Tolga Gaş Hilmi Kılgın Kübra Duvan Aydemir Dilşat Erümit Ruhan Deniz Topuz Ahmet Ulugöl

Abstract

Aims: It has been long suspected that the cannabinoid system participates in the antinociceptive effects of nonsteroidal anti-inflammatory drugs. We studied the possible effects of cannabinoid receptor antagonism on diclofenac-induced antinociception
in the writhing test in mice. Methods: In our study, male BALB/c mice, weighing 20-30 g, were used. Writhing responses were
produced by intraperitoneal injection of 0.6% acetic acid. Different doses of diclofenac (3, 10, 30 mg/kg, i.p.) were tested, then
the influence of AM-251 (1 mg/kg, i.p.), a cannabinoid CB1 receptor antagonist and AM-630 (3 mg/kg, i.p.), a cannabinoid
CB2 receptor antagonist on the antinociceptive effects of diclofenac was studied. Results: Diclofenac administration elicited a
significant, dose-dependent antinociceptive response; however, neither the cannabinoid CB1 receptor antagonist AM-251 nor
the cannabinoid CB2 receptor antagonist AM-630 had any influence on the antinociceptive effect of diclofenac. Conclusion:
Iinhibition of cannabinoid receptors does not contribute to the antinociceptive action of systemic diclofenac. Further studies
are needed to explain the antinociceptive mechanism of diclofenac. Keywords: AM-251, AM-630, antinociception, cannabinoid
receptors, diclofenac

Keywords

AM-251, AM-630, antinociception, cannabinoid receptors, diclofenac

References

• 1. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 2014;31:115-20. 2. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med 2016;48:128-41. 3. Sastre-Garriga J, Vila C, Clissold S et al. THC and CBD oromucosal spray (Sativex (R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627-37. 4. Mallet C, Daulhac L, Bonnefont J et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008;139:190-200. 5. Rogosch T, Sinning C, Podlewski A et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorgan Med Chem 2012;20:101-7. 6. Crunfli F, Vilela FC, Giusti-Paiva A. Cannabinoid CB1 receptors mediate the effects of dipyrone. Clin Exp Pharmacol P 2015;42:246- 55. 7. Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009;2:1-14. 8. Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4:11-20. 9. Fowler CJ. NSAIDs: endocannabinoid stimulating anti-inflammatory drugs?. Trends Pharmacol Sci 2012;33:468-73. 10. Elmas P, Ulugol A. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. J Neural Transm 2013;120:1533-8. 11. Schlosburg JE, Radanova L, Di Marzo V et al. Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behav Pharmacol 2012;23:722-6. 12. Topuz RD, Gunduz O, Karadag HC et al. Endocannabinoid and N-acylethanolamide levels in rat brain and spinal cord following systemic dipyrone and paracetamol administration. Can J Physiol Pharmacol 2019;8:1-7. 13. Saglam G, Gunduz O, Ulugol A. Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol. Acta Neurol Belg 2014;114:307-9. 14. Anikwue R, Huffman JW, Martin ZL et al. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002;303:340-6. 15. Naidu PS, Booker L, Cravatt BF et al. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56. 16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10. 17. Ulugol A, Ozyigit F, Yesilyurt O et al. The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. Anesth Analg 2006;102:443-7. 18. Gencer A, Gunduz O, Ulugol A. Involvement of descending serotonergic and noradrenergic systems and their spinal receptor subtypes in the antinociceptive effect of dipyrone. Drug Res 2015;65:645-9. 19. Yilmaz I, Ulugol A. The effect of nitric oxide synthase inhibitors on the development of analgesic tolerance to dipyrone in mice. Int J Neurosci 2009;119:755-64. 20. Ertin IH, Gunduz O, Ulugol A. Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone. Acta Neuropsychiatr 2015;27:48-52. 21. Vane J, Botting R. Inflammation and the mechanism of action of antiinflammatory drugs. Faseb Journal 1987;1:89-96. 22. Guhring H, Hamza M, Sergejeva M et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002;454:153-63. 23. Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003;76:187-95. 24. Silva LCR, Romero TRL, Guzzo LS et al. Participation of cannabinoid receptors in peripheral nociception induced by some NSAIDs. Braz J Med Biol Res 2012;45:1240-3.